Bp0003 1

Manufactured by BioXCell

The BP0003–1 is a compact and reliable laboratory centrifuge designed for general-purpose applications. It features a robust construction, accommodating sample volumes up to 15 mL, and operates at a maximum speed of 6,000 rpm. The centrifuge provides consistent and accurate separation results, making it a versatile tool for various laboratory procedures.

Automatically generated - may contain errors

Lab products found in correlation

Bp0090, by BioXCell (2 mentions) Bp0061, by BioXCell (2 mentions) Bp0004 1, by BioXCell (1 mentions) Bp0089, by BioXCell (1 mentions) Be0061, by BioXCell (1 mentions) Be0131, by BioXCell (1 mentions) Be0290, by BioXCell (1 mentions) Be0090, by BioXCell (1 mentions) Be0036, by BioXCell (1 mentions) Be0146, by BioXCell (1 mentions) Rmp1 14, by BioXCell (1 mentions)

5 protocols using bp0003 1

CD8 and CD4 T cell depletion

Check if the same lab product or an alternative is used in the 5 most similar protocols

For CD8 and CD4 T cell depletion, anti-CD8 (clone: 53–6.7, BioXcell # BP0004–1) and anti-CD4 (clone: GK1.5, BioXcell # BP0003–1) antibodies were i.p. injected per mouse according to the following regimen: day −1 and day 3 (500 μg), then every 72 hours until experiment endpoint (250 μg) (40 ). As a negative control to CD8 and CD4 depletion, mice from other groups received, by i.p. injection, InVivoPlus rat IgG2a isotype control, anti-trinitrophenol (clone 2A3, BioXcell #BP0089) and InVivoPlus rat IgG2b isotype control, anti-keyhole limpet hemocyanin (clone LTF-2, BioXcell # BP0090), respectively.

Wennerberg E., Mukherjee S., Spada S., Hung C., Agrusa C., Chen C., Valeta-Magara A., Rudqvist N.P., Van Nest S., Kamel M.K., Nasar A., Narula N., Mittal V., Markowitz G., Zhou X.K., Adusumilli P.S., Borczuk A., White T.E., Khan A.G., Balderes P., Lorenz I.C., Altorki N., Demaria S., McGraw T.E, & Stiles B.M. (2022). Expression of the mono-ADP-ribosyltransferase ART1 by tumor cells mediates immune resistance in non-small cell lung cancer. Science translational medicine, 14(636), eabe8195.

+ Open protocol

+ Expand

In vivo immune checkpoint blockade

Check if the same lab product or an alternative is used in the 5 most similar protocols

For in vivo experiments, mice were treated with anti-CTLA-4 (200 µg; Bio X Cell; BE0131) or anti-PD-1 antibody (200 μg; RMP1-14, Bio X Cell; BE0146) three times per week via intraperitoneal injection. Anti-NK1.1 (250 µg; Bio X Cell; BE0036), anti-CD8 (200 µg; Bio X Cell; BE0061), anti-CD4 (200 µg; Bio X Cell; BP00031) or the respective isotype control (Bio X Cell; BE0290 or BE0090) was given twice per week by intraperitoneal injection.

Leibold J., Tsanov K.M., Amor C., Ho Y.J., Sánchez-Rivera F.J., Feucht J., Baslan T., Chen H.A., Tian S., Simon J., Wuest A., Wilkinson J.E, & Lowe S.W. (2024). Somatic mouse models of gastric cancer reveal genotype-specific features of metastatic disease. Nature Cancer, 5(2), 315-329.

+ Open protocol

+ Expand

Depletion of CD4+ and CD8+ T cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

For the depletion of CD4⁺ and CD8⁺ T cells, mice were i.p. injected with 500μg anti-CD4 (BioXCell, BP0003–1) and anti-CD8 antibody (BioXCell, BP0061) every 5 days from 6 to 9.5 months of age or for memory related behavioral experiments from 6 to 8.5 months of age. IgG (BioXCell, BP0090) isotype control was administered at the same frequency and dosage. To characterize the depletion efficiency, mice were acutely treated with 500 μg anti-CD4, or anti-CD8 or IgG. Brain, meninges and blood were extracted for single cell analysis followed by flow cytometry assessment of CD4⁺ and CD8⁺ T cell populations.

Chen X., Firulyova M., Manis M., Herz J., Smirnov I., Aladyeva E., Wang C., Bao X., Finn M.B., Hu H., Shchukina I., Kim M.W., Yuede C.M., Kipnis J., Artyomov M.N., Ulrich J.D, & Holtzman D.M. (2023). Microglia-mediated T cell Infiltration Drives Neurodegeneration in Tauopathy. Nature, 615(7953), 668-677.

+ Open protocol

+ Expand

Antibody-Mediated Immune Modulation

Check if the same lab product or an alternative is used in the 5 most similar protocols

All antibody treatments, anti-CD4 (BioXcell BP0003-1), anti-CD8 (BioXcell BP0061) and IgG2a isotype (BioXcell BP0085), were administered as 200 µg intraperitoneal injections, on days 2, 4, and 6 post-ADT or TRT. 200 µg anti-mouse Gr-1 antibody (clone RB6-8C5) (BD Pharmingen 552985) was administered intraperitoneally three times a week post-TRT administration.

Muralidhar A., Hernandez R., Morris Z.S., Comas Rojas H., Bio Idrissou M., Weichert J.P, & McNeel D.G. (2024). Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy using 90Y-NM600 in combination with androgen deprivation therapy in murine prostate tumors. Journal for Immunotherapy of Cancer, 12(4), e008760.

+ Open protocol

+ Expand

T Cell Depletion Methodology

Check if the same lab product or an alternative is used in the 5 most similar protocols

Anti‐CD4 (GK1.5 clone‐ rat IgG2b, 250 µg, BioXcell, BP0003‐1) or anti‐CD8 mAbs (2.43 clone‐rat IgG2b, 250 µg, BioXcell, BP0061) were injected i.p. one day before and one day after tumor inoculation followed by repeat injections once per week. Eight days after the first i.p. injection, the spleens of the mice were collected to verify the depletion of CD4⁺ and CD8⁺ T cells using flow cytometry. The results showed greater than 99% depletion of each cell subset.

Huang M., Xiong D., Pan J., Zhang Q., Wang Y., Myers C.R., Johnson B.D., Hardy M., Kalyanaraman B, & You M. (2022). Prevention of Tumor Growth and Dissemination by In Situ Vaccination with Mitochondria‐Targeted Atovaquone. Advanced Science, 9(12), 2101267.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!